Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review.
Candy
Bridget
B
Marie Curie Palliative Care Research Unit, Department of Mental Health Sciences, Royal Free and University College Medical School, London, UK. b.candy@medsch.ucl.ac.uk
Jones
Louise
L
Williams
Rachael
R
Tookman
Adrian
A
King
Michael
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D006801:Humans; D018783:Impotence, Vasculogenic / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011468:Prostatectomy / Q000009:adverse effects; D011471:Prostatic Neoplasms / Q000628:therapy*; D011878:Radiotherapy / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D010726:Phosphodiesterase Inhibitors